Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001714899-19-000022
Filing Date
2019-04-18
Accepted
2019-04-18 16:36:07
Documents
5
Period of Report
2019-05-30
Effectiveness Date
2019-04-18

Document Format Files

Seq Description Document Type Size
1 DEF 14A fy18def14aproxy.htm DEF 14A 732513
2 proxyimage5.jpg GRAPHIC 192911
3 proxyimage1a01.jpg GRAPHIC 26538
4 proxyimage1a02.jpg GRAPHIC 26538
5 proxyimage2.jpg GRAPHIC 520967
  Complete submission text file 0001714899-19-000022.txt   1789789
Mailing Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38311 | Film No.: 19756340
SIC: 2836 Biological Products, (No Diagnostic Substances)